ARID1A mutation or loss was associated with immune microenvironmental factors in clear cell ovarian cancer (CCC), suggesting that ARID1A status has potential as a biomarker to guide decisions concerning patient selection for ICB therapy in CCC (20). Here, ARID1A is linked to ovarian clear cell cancer.